Gemcitabine Hydrochloride



Indications and Reactions:

Role Indications Reactions
Primary
Non-small Cell Lung Cancer 26.4%
Pancreatic Carcinoma 9.1%
Prophylaxis 9.1%
Hypertension 5.6%
Adenocarcinoma Pancreas 5.5%
Pain 4.7%
Non-small Cell Lung Cancer Stage Iv 4.6%
Breast Cancer 4.5%
Pancreatic Carcinoma Metastatic 4.3%
Breast Cancer Metastatic 3.7%
Nausea 3.6%
Transitional Cell Carcinoma 3.0%
Constipation 2.9%
Diabetes Mellitus 2.5%
Product Used For Unknown Indication 2.1%
Non-hodgkin's Lymphoma 1.8%
Pelvic Neoplasm 1.7%
Bladder Cancer 1.6%
Prophylaxis Of Nausea And Vomiting 1.6%
Neoplasm 1.6%
Pulmonary Embolism 10.7%
Thrombocytopenia 9.6%
Pneumonia 8.8%
Vomiting 7.8%
Neutropenia 7.2%
Death 5.7%
Dehydration 5.7%
Hepatic Steatosis 4.7%
Sepsis 4.7%
Gastrointestinal Toxicity 4.5%
Interstitial Lung Disease 4.3%
Cholangitis 3.9%
Thrombosis 3.3%
General Physical Health Deterioration 3.1%
Deep Vein Thrombosis 2.9%
Pyrexia 2.9%
Posterior Reversible Encephalopathy Syndrome 2.7%
Neutropenic Sepsis 2.5%
Thrombotic Microangiopathy 2.5%
Febrile Neutropenia 2.3%
Secondary
Product Used For Unknown Indication 44.5%
Adenocarcinoma Pancreas 17.6%
Non-small Cell Lung Cancer 7.9%
Prophylaxis 6.2%
Pancreatic Carcinoma 4.4%
Diabetes Mellitus 3.0%
Insomnia 1.8%
Hypertension 1.5%
Chemotherapy 1.3%
Transitional Cell Carcinoma 1.2%
Breast Cancer 1.2%
Non-hodgkin's Lymphoma 1.2%
Constipation 1.2%
Pancreatic Carcinoma Metastatic 1.1%
Diarrhoea 1.1%
Nausea 1.1%
Hodgkin's Disease 1.0%
Adenocarcinoma 0.9%
Pain 0.9%
Cancer Pain 0.8%
White Blood Cell Count Decreased 23.2%
Rash 15.6%
Platelet Count Decreased 5.8%
Cholecystitis Acute 4.6%
Interstitial Lung Disease 4.2%
Neutrophil Count Decreased 4.2%
Pyrexia 4.2%
Stomatitis 4.1%
Anaemia 3.7%
Death 3.4%
Malignant Neoplasm Progression 3.2%
Neutropenia 3.2%
Thrombocytopenia 3.2%
Vomiting 3.0%
Cholangitis 2.7%
Blood Bilirubin Increased 2.5%
Skin Disorder 2.5%
Pneumonia 2.3%
Ulcerative Keratitis 2.3%
Diarrhoea 2.1%
Concomitant
Product Used For Unknown Indication 48.7%
Adenocarcinoma Pancreas 21.6%
Pancreatic Carcinoma 8.3%
Pain 2.7%
Non-small Cell Lung Cancer 2.5%
Breast Cancer Metastatic 2.5%
Small Intestine Carcinoma 2.0%
Diffuse Large B-cell Lymphoma 1.7%
Prophylaxis 1.6%
Lung Adenocarcinoma Recurrent 1.3%
Breast Cancer 1.1%
Pancreatic Carcinoma Non-resectable 0.9%
Hypertension 0.8%
Ovarian Cancer 0.8%
Pancreatic Carcinoma Stage Iv 0.8%
Metastatic Renal Cell Carcinoma 0.7%
Bile Duct Cancer 0.6%
Transitional Cell Carcinoma 0.6%
Brain Oedema 0.5%
Candida Infection 0.4%
Intra-abdominal Haemorrhage 14.0%
Rash 12.4%
Decubitus Ulcer 10.1%
Skin Disorder 9.6%
Vomiting 7.9%
Pulmonary Embolism 7.3%
Decreased Appetite 6.2%
Proteinuria 5.1%
Disseminated Intravascular Coagulation 3.4%
Anaemia 2.8%
Nausea 2.8%
Neoplasm Malignant 2.8%
White Blood Cell Count Increased 2.8%
Cholangitis 2.2%
Dermatitis Acneiform 2.2%
Deep Vein Thrombosis 1.7%
Drug Level Increased 1.7%
Malignant Pleural Effusion 1.7%
Off Label Use 1.7%
Platelet Count Increased 1.7%